



**FOR IMMEDIATE RELEASE  
NEWS RELEASE**

TSX Venture: **AMF**

**AMORFIX LIFE SCIENCES LTD. REPORTS SECOND QUARTER RESULTS  
FOR FISCAL YEAR 2006**

TORONTO, ON, November 25, 2005 – Amorfix Life Sciences Ltd. (TSX-V – AMF) today reported commercialization progress and financial results for the three and six month periods ended September 30, 2005.

**Second Quarter Highlights**

- The company has improved the EP-vCJD™ test to be 1,000 times more sensitive than conventional immunoassays and is able to detect brain prions added into blood. The company is now beginning to confirm the test for endogenous prions in the blood of animals with prion diseases and expects this first significant technical milestone to be reached by the end of December. This is a prerequisite to access the tissue bank of samples of human blood from patients with vCJD for validation of the test for screening of human blood for transfusion.
- Completed the amalgamation with Luxor Developments Inc. on September 21, 2005, on which date Amorfix became a reporting issuer under the securities laws of British Columbia and Alberta. Amorfix began trading on the TSX Venture exchange on October 3, 2005.
- Completed the private placement financing of 6,000,000 common share units at \$0.50 per unit and received gross proceeds of \$3 million (net of cash costs of \$296,160). Each common share unit consists of one common share and one-half common share purchase warrant. Each full common share purchase warrant entitles the holder to acquire one common share at an exercise price of \$0.75 per share until October 3, 2006.
- Established new laboratory facilities and received approval for use of the Level 2 laboratory at Sunnybrook. On completion of the financing, we have also hired additional technical and support personnel.

“In the second quarter, we successfully capitalized the Company, established lab facilities and added to our team. We also welcome the former Luxor shareholders to Amorfix. Our research team continues to make significant progress on our EP-vCJD™ diagnostic test and recent scientific discoveries regarding prions have demonstrated an even greater need for the detection of prions in blood”, said Dr. George Adams, President and CEO.

**Financial Results**

Amorfix was formed in January 2004 to commercialize the epitope protection (EP) technologies discovered at the University of Toronto by Dr. Cashman and Dr. Lehto. No expenses were incurred by the company until September 2004. The results of the comparative periods in fiscal 2004 have only limited expenses as the Company was initiating its efforts to file patents and seek financing.

For the three months and six months ended September 30, 2005, the investment income earned resulted from interest on short-term bank certificate deposits which resulted mainly from the investment of the net proceeds of the \$3 million financing completed on September 21, 2005.

Research and development expenses for the three months ended September 30, 2005 increased to \$214,818 reflecting the start up costs for establishing new laboratory facilities at the Sunnybrook and Women's College Health Sciences Centre and the hiring of additional research and development personnel for development activities related to the vCJD blood detection assay. For the three months and six months ended September 31, 2005, research and development salaries and personnel-related expenses were \$141,259 and \$248,517, respectively, and laboratory and research and development program expenses amounted to \$73,559 and \$79,340, respectively.

For the three months and six months ended September 30, 2005, general and administration costs consisted primarily of salaries, stock-based compensation expense and advisory fees.

Interest expense for the three months and six months ended September 30, 2005, related to promissory notes payable to Luxor which were bearing interest at 6% per annum. The promissory notes were eliminated on amalgamation.

The net loss for the three months and six months ended September 30, 2005 was \$275,350 and \$429,979, respectively.

#### **Amorfix Life Sciences Ltd.**

(a development stage company)

#### **INTERIM STATEMENTS OF OPERATIONS AND DEFICIT**

|   | Three Months Ended<br>September 30, |             | Six Months Ended<br>September 30, |             | Cumulative from<br>inception to<br>September 30, |
|---|-------------------------------------|-------------|-----------------------------------|-------------|--|
|   | 2005                                | 2004        | 2005                              | 2004        | 2005   |
|   | (unaudited)                         |             | (unaudited)                       |             | (unaudited)                                      |
| <b>Revenues</b>                           |                                     |             |                                   |             |  |
| Investment income                         | \$ 2,121                            | \$ -        | \$ 2,821                          | \$ -        | \$ 2,821   |
| <b>Expenses</b>                           |                                     |             |                                   |             |  |
| Research and development                  | 214,818                             | 4,499       | 327,857                           | 4,499       | 393,776  |
| General and administrative                | 56,299                              | 15,026      | 98,219                            | 15,026      | 196,031  |
| Amortization expense                      | 4,801                               | 0           | 4,801                             | 0           | 4,801  |
| Interest expense                          | 1,553                               | 0           | 1,923                             | 0           | 3,196  |
|   | 277,471                             | 19,525      | 432,800                           | 19,525      | 597,804  |
| Net loss                                  | (275,350)                           | (19,525)    | (429,979)                         | (19,525)    | (594,983)  |
| Deficit, beginning of period              | (319,633)                           | 0           | (165,004)                         | 0           | 0  |
| Reverse takeover of Luxor (note 1e)       | (479,693)                           | 0           | (479,693)                         | 0           | (479,693)  |
| Deficit, end of period                    | \$ (1,074,676)                      | \$ (19,525) | \$ (1,074,676)                    | \$ (19,525) | \$ (1,074,676)                                   |
| Loss per common share - basic and diluted | \$ (0.019)                          | \$ (0.006)  | \$ (0.030)                        | \$ (0.009)  |  |
| Weighted average number of common shares  | 14,736,264                          | 3,098,901   | 14,230,632                        | 2,060,440   |  |

## About Amorfix

Amorfix is an emerging theranostics company focused on the diagnosis and treatment of neurodegenerative diseases, where aggregated misfolded proteins (AMPs) are prevalent. These include aggregated misfolded prion protein which makes up “prions,” the infectious agents of the Transmissible Spongiform Encephalopathies (TSE), such as Bovine Spongiform Encephalopathy (BSE or "mad cow disease") and the human form, variant Creutzfeldt-Jakob Disease (vCJD), as well as degenerative diseases such as Alzheimer’s Disease (AD), Amyotrophic Lateral Sclerosis (ALS) and Parkinson’s Disease (PD). Amorfix was formed to commercialize the discoveries of the epitope protection (EP) technologies. These discoveries position the company to become the world authority on AMP diseases. The company will use this new knowledge to develop diagnostic kits, therapeutics and prophylactics for AMP diseases.

For further information, please contact:

Dr. George Adams, President and CEO  
Amorfix Life Sciences Ltd.  
416-557-4647

James Parsons, CFO  
Amorfix Life Sciences Ltd.  
416-705-5686

**The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Actual future results may differ materially from those contemplated. The risks, uncertainties and other factors that could influence the actual results are described in documents filed with regulatory authorities.**